RDY:NYSE
Dr Reddy's Laboratories Ltd
USD 12.75
arrow_downward
-0.16%(-0.020) 1H
USD 12.75
0.00% (0.00)
bedtimeSelepas waktu pejabat
Ditutup: 14 Okt, 4:00:05 PTG GMT-4 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk RDY...
Buka
USD 12.70
Tinggi
USD 12.94
Rendah
USD 12.65
Permodalan Pasaran
10.77B
Purata volum
3.17J
Volum
0.00
Dividen
0.65%
Dividen suku tahunan
USD 0.02
Tarikh tanpa dividen
10 Jul 2026
Nisbah H/P
30.58
tgi 52 mgu
USD 15.67
rdh 52 mgu
USD 11.36
EPS
USD 0.42
Beta
0.30
Syer tertunggak
834.64J
Bilangan pekerja
28K
Buka
USD 12.70
Tinggi
USD 12.94
Rendah
USD 12.65
Permodalan Pasaran
10.77B
Purata volum
3.17J
Volum
0.00
Dividen
0.65%
Dividen suku tahunan
USD 0.02
Tarikh tanpa dividen
10 Jul 2026
Nisbah H/P
30.58
tgi 52 mgu
USD 15.67
rdh 52 mgu
USD 11.36
EPS
USD 0.42
Beta
0.30
Syer tertunggak
834.64J
Bilangan pekerja
28K
Cerita berita
Daripada sumber web dan rakan kongsi berita
MarketBeat
·
5 jam lalu
Dr. Reddy's Laboratories (NYSE:RDY) Shares Cross Above Two Hundred Day Moving Average - Time to Sell?
Equitypandit
·
7 jam lalu
Stocks in Focus: Dr Reddy’s Lab, Enviro Infra, and Others
Business Today
·
8 jam lalu
Dr Reddy's Laboratories stock in focus as USFDA completes pre-approval inspection at FTO-9 plant
Profil
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Perihal Dr Reddy's Laboratories Ltd
CEOErez Israeli
Pekerja27.5K
Diasaskan1984
Ibu pejabatHyderabad, Andhra Pradesh, India
Sektor-
Laman webdrreddys.com